These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 20483490)
1. Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia-reperfusion injury? Gavins FN Trends Pharmacol Sci; 2010 Jun; 31(6):266-76. PubMed ID: 20483490 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199 [TBL] [Abstract][Full Text] [Related]
6. Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways. Bozinovski S; Anthony D; Anderson GP; Irving LB; Levy BD; Vlahos R Pharmacol Ther; 2013 Dec; 140(3):280-9. PubMed ID: 23880288 [TBL] [Abstract][Full Text] [Related]
7. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1. Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291 [TBL] [Abstract][Full Text] [Related]
8. A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects. Hecht I; Rong J; Sampaio AL; Hermesh C; Rutledge C; Shemesh R; Toporik A; Beiman M; Dassa L; Niv H; Cojocaru G; Zauberman A; Rotman G; Perretti M; Vinten-Johansen J; Cohen Y J Pharmacol Exp Ther; 2009 Feb; 328(2):426-34. PubMed ID: 19023040 [TBL] [Abstract][Full Text] [Related]
9. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis. Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury. Ansari J; Kaur G; Gavins FNE Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29659553 [TBL] [Abstract][Full Text] [Related]
11. Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct. Gavins FN; Kamal AM; D'Amico M; Oliani SM; Perretti M FASEB J; 2005 Jan; 19(1):100-2. PubMed ID: 15507472 [TBL] [Abstract][Full Text] [Related]
12. Insights into the Activation Mechanism of the ALX/FPR2 Receptor. Schmitz Nunes V; Rogério AP; Abrahão O J Phys Chem Lett; 2020 Nov; 11(21):8952-8957. PubMed ID: 33030905 [TBL] [Abstract][Full Text] [Related]
13. The formyl peptide receptor agonist FPRa14 induces differentiation of Neuro2a mouse neuroblastoma cells into multiple distinct morphologies which can be specifically inhibited with FPR antagonists and FPR knockdown using siRNA. Cussell PJG; Howe MS; Illingworth TA; Gomez Escalada M; Milton NGN; Paterson AWJ PLoS One; 2019; 14(6):e0217815. PubMed ID: 31170199 [TBL] [Abstract][Full Text] [Related]
14. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes. Stepniewski TM; Filipek S Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522 [TBL] [Abstract][Full Text] [Related]
15. Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology. Tylek K; Trojan E; Regulska M; Lacivita E; Leopoldo M; Basta-Kaim A Pharmacol Rep; 2021 Aug; 73(4):1004-1019. PubMed ID: 34105114 [TBL] [Abstract][Full Text] [Related]
16. Resolvin D1 protects the liver from ischemia/reperfusion injury by enhancing M2 macrophage polarization and efferocytosis. Kang JW; Lee SM Biochim Biophys Acta; 2016 Sep; 1861(9 Pt A):1025-1035. PubMed ID: 27317426 [TBL] [Abstract][Full Text] [Related]
17. Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease. Vital SA; Becker F; Holloway PM; Russell J; Perretti M; Granger DN; Gavins FN Circulation; 2016 May; 133(22):2169-79. PubMed ID: 27154726 [TBL] [Abstract][Full Text] [Related]
18. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Petri MH; Laguna-Fernández A; Gonzalez-Diez M; Paulsson-Berne G; Hansson GK; Bäck M Cardiovasc Res; 2015 Jan; 105(1):65-74. PubMed ID: 25341894 [TBL] [Abstract][Full Text] [Related]
19. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition. Schepetkin IA; Khlebnikov AI; Giovannoni MP; Kirpotina LN; Cilibrizzi A; Quinn MT Curr Med Chem; 2014; 21(13):1478-504. PubMed ID: 24350845 [TBL] [Abstract][Full Text] [Related]
20. FPR2/ALX activation reverses LPS-induced vascular hyporeactivity in aorta and increases survival in a pneumosepsis model. Horewicz VV; Crestani S; de Sordi R; Rezende E; Assreuy J Eur J Pharmacol; 2015 Jan; 746():267-73. PubMed ID: 25478948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]